Accepted statements related to general issues with vaccines, need for SARS-CoV-2 vaccination, timing, and prioritisation for patients with IBD by the IOIBD
| Accepted statements | Proportion agreement | Strength of agreement (Mean) | SD |
| General issues of vaccines in IBD | |||
| Vaccinations are not associated with the onset of IBD. | 95.3% | 9.22 | 1.53 |
| Vaccinations are not associated with exacerbation of IBD. | 95.3% | 9.16 | 1.31 |
| Patients with IBD, irrespective of whether they are receiving immune-modifying therapies, can safely receive all non-live vaccinations for vaccine-preventable illnesses. | 100% | 9.47 | 0.76 |
| Patients with IBD who are receiving immune-modifying therapies should not receive live virus vaccines while they are receiving their immune-modifying therapies. | 85.9% | 8.27 | 1.95 |
| Patients with IBD are able to mount an immune response to various vaccines, although immune-modifying therapies partially blunt that response. | 98.4% | 8.79 | 1.08 |
| Patients with IBD receiving infliximab infusions can receive non-live vaccinations on the day of their infusion or in mid-cycle without reduction in efficacy and safety. | 87.5% | 8.22 | 1.65 |
| Risk of COVID-19 to patients with IBD and need for SARS-CoV-2 vaccination | |||
| Patients with IBD are at the same risk of infection with SARS-CoV-2 as compared with the general population. | 90.6% | 8.55 | 1.61 |
| Patients with IBD should be vaccinated against SARS-CoV-2. | 98.4% | 9.20 | 1.12 |
| Timing of when to receive SARS-CoV-2 vaccination | |||
| The best time to administer SARS-CoV-2 vaccination in patients with IBD is at the earliest opportunity to do so. | 95.3% | 8.91 | 1.27 |
| Disease activity of IBD should not impact the timing of SARS-CoV-2 vaccination. | 90.0% | 8.50 | 1.55 |
| Vaccination against SARS-CoV-2 is unlikely to cause a flare of IBD. | 89.1% | 8.31 | 1.38 |
| SARS-CoV-2 vaccination can be administered to patients with IBD during induction with biologic therapies irrespective of timing within the treatment cycle. | 97.5% | 8.33 | 1.14 |
| SARS-CoV-2 vaccination can be administered to patients with IBD on maintenance biologic therapies irrespective of timing within the treatment cycle. | 100% | 8.93 | 1.00 |
| The prioritisation of patients with IBD for SARS-CoV-2 vaccination | |||
| Healthcare/essential workers with IBD should be vaccinated in the same prioritisation tier as healthcare/essential workers without IBD. | 92.2% | 8.84 | 2.00 |
| Individuals who are not healthcare/essential workers and have no risk factors for complications of COVID-19 but have IBD should be vaccinated in the same prioritisation tier as those who are non-healthcare/essential workers and have no risk factors for SARS-COV2. | 82.5% | 8.02 | 2.03 |
| Individuals at increased risk for complications of COVID-19 based on age or comorbidities who also have IBD should be vaccinated in the same prioritisation tier as individuals at increased risk for complications of COVID-19 without IBD. | 96.8% | 9.13 | 1.07 |
| Individuals with IBD who are on immune-modifying therapies but are not otherwise at risk for complications of COVID-19 should be vaccinated in the same prioritisation tier as those who are ‘immunocompromised’. | 81.3% | 8.09 | 1.80 |
| Once SARS-CoV-2 vaccinations are authorised for children, guidance for vaccination of children with IBD will be the same as for children without IBD. | 100% | 8.90 | 1.03 |
| Household contacts of patients with IBD are encouraged to receive SARS-CoV-2 vaccination. | 97.4% | 9.08 | 1.34 |
| Household contacts of patients with IBD should avoid live, replication-competent SARS-CoV-2 vaccination. | 81.6% | 7.71 | 2.04 |
| Women with IBD planning pregnancy should be encouraged to receive the SARS-CoV-2 vaccine prior to attempting conception, but not delay conception solely to wait for vaccination. | 100% | 8.87 | 1.03 |
| SARS-CoV-2 vaccines should be offered to pregnant women with IBD in accordance with regional recommendations for pregnant women without IBD. | 100% | 8.97 | 1.07 |
| SARS-CoV-2 vaccines should be offered to lactating women with IBD in accordance with regional recommendations for lactating women without IBD. | 100% | 8.81 | 1.08 |